PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. BNTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


MRNABNTX
YTD Return33.63%-14.15%
1Y Return6.04%-13.66%
3Y Return (Ann)-5.91%-22.16%
Sharpe Ratio0.11-0.40
Daily Std Dev51.73%34.79%
Max Drawdown-85.65%-80.48%
Current Drawdown-72.57%-79.47%

Fundamentals


MRNABNTX
Market Cap$44.96B$22.09B
EPS-$15.60$0.50
PE Ratio24.73183.34
PEG Ratio0.000.04
Revenue (TTM)$5.15B$2.73B
Gross Profit (TTM)$10.55B$16.07B
EBITDA (TTM)-$4.56B-$46.90M

Correlation

-0.50.00.51.00.6

The correlation between MRNA and BNTX is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Performance

MRNA vs. BNTX - Performance Comparison

In the year-to-date period, MRNA achieves a 33.63% return, which is significantly higher than BNTX's -14.15% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


400.00%500.00%600.00%700.00%800.00%December2024FebruaryMarchAprilMay
838.56%
544.73%
MRNA
BNTX

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Moderna, Inc.

BioNTech SE

Risk-Adjusted Performance

MRNA vs. BNTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and BioNTech SE (BNTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MRNA
Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at 0.11, compared to the broader market-2.00-1.000.001.002.003.004.000.11
Sortino ratio
The chart of Sortino ratio for MRNA, currently valued at 0.59, compared to the broader market-4.00-2.000.002.004.006.000.59
Omega ratio
The chart of Omega ratio for MRNA, currently valued at 1.07, compared to the broader market0.501.001.502.001.07
Calmar ratio
The chart of Calmar ratio for MRNA, currently valued at 0.07, compared to the broader market0.002.004.006.000.07
Martin ratio
The chart of Martin ratio for MRNA, currently valued at 0.21, compared to the broader market-10.000.0010.0020.0030.000.21
BNTX
Sharpe ratio
The chart of Sharpe ratio for BNTX, currently valued at -0.40, compared to the broader market-2.00-1.000.001.002.003.004.00-0.40
Sortino ratio
The chart of Sortino ratio for BNTX, currently valued at -0.38, compared to the broader market-4.00-2.000.002.004.006.00-0.38
Omega ratio
The chart of Omega ratio for BNTX, currently valued at 0.96, compared to the broader market0.501.001.502.000.96
Calmar ratio
The chart of Calmar ratio for BNTX, currently valued at -0.17, compared to the broader market0.002.004.006.00-0.17
Martin ratio
The chart of Martin ratio for BNTX, currently valued at -0.72, compared to the broader market-10.000.0010.0020.0030.00-0.72

MRNA vs. BNTX - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is 0.11, which is higher than the BNTX Sharpe Ratio of -0.40. The chart below compares the 12-month rolling Sharpe Ratio of MRNA and BNTX.


Rolling 12-month Sharpe Ratio-1.00-0.500.00December2024FebruaryMarchAprilMay
0.11
-0.40
MRNA
BNTX

Dividends

MRNA vs. BNTX - Dividend Comparison

Neither MRNA nor BNTX has paid dividends to shareholders.


TTM20232022
MRNA
Moderna, Inc.
0.00%0.00%0.00%
BNTX
BioNTech SE
0.00%0.00%1.41%

Drawdowns

MRNA vs. BNTX - Drawdown Comparison

The maximum MRNA drawdown since its inception was -85.65%, which is greater than BNTX's maximum drawdown of -80.48%. Use the drawdown chart below to compare losses from any high point for MRNA and BNTX. For additional features, visit the drawdowns tool.


-84.00%-82.00%-80.00%-78.00%-76.00%-74.00%-72.00%December2024FebruaryMarchAprilMay
-72.57%
-79.47%
MRNA
BNTX

Volatility

MRNA vs. BNTX - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 15.84% compared to BioNTech SE (BNTX) at 6.18%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than BNTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%December2024FebruaryMarchAprilMay
15.84%
6.18%
MRNA
BNTX

Financials

MRNA vs. BNTX - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and BioNTech SE. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items